^
    Back
    Association details:
    Biomarker:HER-2 H878Y
    Cancer:Non Small Cell Lung Cancer
    Drug:gefitinib (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    PLoS One
    Title:

    Differential Sensitivity of ERBB2 Kinase Domain Mutations towards Lapatinib

    Excerpt:
    ...similar to EGFR-L858R that was reported as gefitinib-sensitizing mutation in NSCLC.
    DOI:
    10.1371/journal.pone.0026760